Hyunkyung Cha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyunkyung Cha has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Dae Woo Kim
Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
5 shared publications - Seung-No Hong
Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - Ara Jo
Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
3 shared publications - Hee-Suk Lim
Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Hyun Jik Kim
Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Jin-A Park
Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 11 January 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (1)
Prolonged persistence of tissue‐resident memory cells in the upper airway following SARS ‐ CoV ‐2 infection and vaccination
Objectives: Here, we characterised the diversity and persistence of immunological memory cells—particularly tissue‐resident memory T (T RM ) and B (B RM ) cells—in the nasopharyngeal lymphoid tissues of healthy vaccinated (HV) individuals and those who experienced SARS‐CoV‐2 breakthrough infection (BR). Methods: Nasopharynx (NP) samples were obtained using brushing from HV and BR subjects. Immune cell populations were analysed using transcriptomic profiling and flow cytometry. Results: Transcriptomic profiling revealed that the NP of SARS‐CoV‐2‐infected individuals exhibited distinctive signatures of lymphocyte‐mediated immunity, underscoring its role as a key site for viral invasion and immune activation. Effector memory CD4+ and CD8+ T (T EM ) cells, along with non‐germinal center (GC) B cells, predominated in the NP. Although overall frequencies of memory T cells were comparable between HV and BR groups, CD4+ T EM and GC B cells were significantly enriched in the NP of BR individuals at least 1 year post infection. Notably, over 80% of CD4+ T EM and 40% of CD8+ T EM cells were T RM , and more than 30% of memory B cells exhibited a B RM phenotype. These populations of CD4+, CD8+ T RM and B RM persisted in the NP for over 2 years following SARS‐CoV‐2 infection or vaccination. In particular, CD4+ T RM cells were significantly more abundant and durably maintained in the NP mucosa of BR individuals. Conclusion: Our findings identify the nasopharynx as a key site of long‐lived immunological memory, marked by persistent T RM and B RM cells after SARS‐CoV‐2 exposure.
- 11 January 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (1)
Open AccessProlonged persistence of tissue‐resident memory cells in the upper airway following SARS ‐ CoV ‐2 infection and vaccination
Objectives: Here, we characterised the diversity and persistence of immunological memory cells—particularly tissue‐resident memory T (T RM ) and B (B RM ) cells—in the nasopharyngeal lymphoid tissues of healthy vaccinated (HV) individuals and those who experienced SARS‐CoV‐2 breakthrough infection (BR). Methods: Nasopharynx (NP) samples were obtained using brushing from HV and BR subjects. Immune cell populations were analysed using transcriptomic profiling and flow cytometry. Results: Transcriptomic profiling revealed that the NP of SARS‐CoV‐2‐infected individuals exhibited distinctive signatures of lymphocyte‐mediated immunity, underscoring its role as a key site for viral invasion and immune activation. Effector memory CD4+ and CD8+ T (T EM ) cells, along with non‐germinal center (GC) B cells, predominated in the NP. Although overall frequencies of memory T cells were comparable between HV and BR groups, CD4+ T EM and GC B cells were significantly enriched in the NP of BR individuals at least 1 year post infection. Notably, over 80% of CD4+ T EM and 40% of CD8+ T EM cells were T RM , and more than 30% of memory B cells exhibited a B RM phenotype. These populations of CD4+, CD8+ T RM and B RM persisted in the NP for over 2 years following SARS‐CoV‐2 infection or vaccination. In particular, CD4+ T RM cells were significantly more abundant and durably maintained in the NP mucosa of BR individuals. Conclusion: Our findings identify the nasopharynx as a key site of long‐lived immunological memory, marked by persistent T RM and B RM cells after SARS‐CoV‐2 exposure.
- Open Access
- 27 November 2025
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 19 (3) , 267-280
Responses of nasal polyp-derived macrophages to inflammatory cues and potential pathological roles in type 2 chronic rhinosinusitis with nasal polyps
Objectives. The role of highly plastic and heterogeneous macrophages in the pathogenesis of nasal polyps (NP) is not well understood. We aimed to investigate the distribution and responses of NP-derived macrophages to inflammatory cues according to endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP).Methods. The distribution of macrophage subsets was analyzed using NP bulk RNA sequencing data with CIBERSORTx program. The cytokines and chemokines produced by NP-derived macrophages following stimulation with interleukin (IL)-4, staphylococcal enterotoxin B (SEB), and lipopolysaccharide were evaluated using a multiplex cytokine assay. Immunofluorescence staining in NP tissues was conducted to validate the findings.Results. Type 2 CRSwNP exhibited a significantly higher proportion of M2 macrophages, whereas both M1 and M2 macrophage populations were elevated in non-type 2 CRSwNP. Baseline cytokine analysis of NP-derived macrophages revealed an increase in thymic stromal lymphopoietin (TSLP) levels in CRSwNP compared to controls. Furthermore, TSLP expression was significantly upregulated from baseline levels following IL-4 or SEB stimulation in type 2 CRSwNP. Notably, IL-4 stimulation led to an increase in oncostatin M (OSM) only in type 2 CRSwNP. Additionally, the number and proportion of TSLP- and OSM-expressing cells among CD163-positive cells were significantly higher in the NP of type 2 CRSwNP patients.Conclusion. NP-derived macrophages from type 2 CRSwNP exhibit elevated expression of TSLP and OSM in response to IL-4 or SEB, potentially contributing to the pathophysiology of type 2 CRSwNP.
- 27 November 2025
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 19 (3) , 267-280
Open AccessResponses of nasal polyp-derived macrophages to inflammatory cues and potential pathological roles in type 2 chronic rhinosinusitis with nasal polyps
Objectives. The role of highly plastic and heterogeneous macrophages in the pathogenesis of nasal polyps (NP) is not well understood. We aimed to investigate the distribution and responses of NP-derived macrophages to inflammatory cues according to endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP).Methods. The distribution of macrophage subsets was analyzed using NP bulk RNA sequencing data with CIBERSORTx program. The cytokines and chemokines produced by NP-derived macrophages following stimulation with interleukin (IL)-4, staphylococcal enterotoxin B (SEB), and lipopolysaccharide were evaluated using a multiplex cytokine assay. Immunofluorescence staining in NP tissues was conducted to validate the findings.Results. Type 2 CRSwNP exhibited a significantly higher proportion of M2 macrophages, whereas both M1 and M2 macrophage populations were elevated in non-type 2 CRSwNP. Baseline cytokine analysis of NP-derived macrophages revealed an increase in thymic stromal lymphopoietin (TSLP) levels in CRSwNP compared to controls. Furthermore, TSLP expression was significantly upregulated from baseline levels following IL-4 or SEB stimulation in type 2 CRSwNP. Notably, IL-4 stimulation led to an increase in oncostatin M (OSM) only in type 2 CRSwNP. Additionally, the number and proportion of TSLP- and OSM-expressing cells among CD163-positive cells were significantly higher in the NP of type 2 CRSwNP patients.Conclusion. NP-derived macrophages from type 2 CRSwNP exhibit elevated expression of TSLP and OSM in response to IL-4 or SEB, potentially contributing to the pathophysiology of type 2 CRSwNP.
- Open Access
- 30 November 2024
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 17 (4) , 317-325
Therapeutic Effectiveness of SNOT 22-Based Interdose Interval Adjustment of Dupilumab for Chronic Rhinosinusitis With Nasal Polyps
Objectives. This study evaluates the enduring efficacy and patient satisfaction of dupilumab with interdose interval adjustments based on the Sino-Nasal Outcome Test (SNOT-22) in chronic rhinosinusitis with nasal polyps (CRSwNP).Methods. A retrospective analysis was conducted on 44 patients who had been treated with dupilumab for over 6 months. This study targeted individuals diagnosed with CRSwNP according to the 2020 edition of the European Position Paper on Rhinosinusitis and Nasal Polyps Criteria. The treatment involved an add-on dupilumab regimen, where the interdose interval was adjusted based on the SNOT-22 scores. Dosage adjustments were made such that patients with initial SNOT-22 scores greater than 40 were tapered to a target level of 20 or less. Similarly, for patients with initial scores of 40 or less, the treatment aimed for an improvement of 50% or more. At each visit, the effectiveness of the treatment was evaluated using SNOT-22, nasal polyp scores (NPS), and a subjective satisfaction questionnaire adapted from the Treatment Satisfaction Questionnaire for Medication (TSQM v.1.4).Results. The adjustment of the interdose interval for dupilumab based on SNOT-22 scores demonstrated sustained improvements in patients’ subjective symptoms, satisfaction, and NPS. The mean (standard deviation) SNOT-22 scores significantly decreased from 46.04 (22.30) to 14.72 (13.66) over 6 months (P<0.001). Similarly, NPS scores improved from 3.20 (2.24) to 1.72 (1.46) within the same period (P<0.001). Satisfaction scores, ranging from 0 to 5, consistently remained above 3.5 for up to 6 months (P=0.166). Additionally, there was a significant correlation between the improvement in the nasal symptom domain of the SNOT-22 scores and higher satisfaction scores.Conclusion. Adjusting dupilumab dosing intervals based on SNOT-22 scores from the outset resulted in sustained efficacy and patient satisfaction in Korean patients with CRSwNP. This approach will meaningfully assist clinicians in determining the optimal dupilumab dosing interval.
- 30 November 2024
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 17 (4) , 317-325
Open AccessTherapeutic Effectiveness of SNOT 22-Based Interdose Interval Adjustment of Dupilumab for Chronic Rhinosinusitis With Nasal Polyps
Objectives. This study evaluates the enduring efficacy and patient satisfaction of dupilumab with interdose interval adjustments based on the Sino-Nasal Outcome Test (SNOT-22) in chronic rhinosinusitis with nasal polyps (CRSwNP).Methods. A retrospective analysis was conducted on 44 patients who had been treated with dupilumab for over 6 months. This study targeted individuals diagnosed with CRSwNP according to the 2020 edition of the European Position Paper on Rhinosinusitis and Nasal Polyps Criteria. The treatment involved an add-on dupilumab regimen, where the interdose interval was adjusted based on the SNOT-22 scores. Dosage adjustments were made such that patients with initial SNOT-22 scores greater than 40 were tapered to a target level of 20 or less. Similarly, for patients with initial scores of 40 or less, the treatment aimed for an improvement of 50% or more. At each visit, the effectiveness of the treatment was evaluated using SNOT-22, nasal polyp scores (NPS), and a subjective satisfaction questionnaire adapted from the Treatment Satisfaction Questionnaire for Medication (TSQM v.1.4).Results. The adjustment of the interdose interval for dupilumab based on SNOT-22 scores demonstrated sustained improvements in patients’ subjective symptoms, satisfaction, and NPS. The mean (standard deviation) SNOT-22 scores significantly decreased from 46.04 (22.30) to 14.72 (13.66) over 6 months (P<0.001). Similarly, NPS scores improved from 3.20 (2.24) to 1.72 (1.46) within the same period (P<0.001). Satisfaction scores, ranging from 0 to 5, consistently remained above 3.5 for up to 6 months (P=0.166). Additionally, there was a significant correlation between the improvement in the nasal symptom domain of the SNOT-22 scores and higher satisfaction scores.Conclusion. Adjusting dupilumab dosing intervals based on SNOT-22 scores from the outset resulted in sustained efficacy and patient satisfaction in Korean patients with CRSwNP. This approach will meaningfully assist clinicians in determining the optimal dupilumab dosing interval.
- Open Access
- 30 November 2023
- Published by Korean Rhinologic Society in Journal of Rhinology
- Vol. 30 (3) , 155-160
A Survey on Biologics for the Treatment of Chronic Rhinosinusitis With Nasal Polyps Among Members of the Korean Rhinologic Society
Background and Objectives: In 2021, biologics were approved for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in Korea. However, CRS is a heterogeneous disease, and its characteristics are thought to differ between Western and Korean populations. This study aimed to evaluate the experiences of members of the Korean Rhinologic Society during the first year of biologic usage for the treatment of nasal polyps.Methods: An anonymous survey consisting of 15 items was conducted from November to December 2021. The survey included questions about participant demographics, use of biologics for treating CRSwNP, and expectations regarding the effectiveness of biologics for treating CRSwNP.Results: In total, 44 members participated in the survey. Approximately half of the respondents were in their 40s (50.0%) and had 5–9 years of clinical experience as otorhinolaryngologists (47.7%). The majority of participants held academic positions (95.4%). About half of them worked in Gyeonggi Province. The utilization of biologics did not differ significantly based on clinical experience (p=0.192). When asked about the factors considered for prescribing biologics, the most common reason was recurrence of polyps after surgery (87.2%). The most frequent reason for discontinuing biologics was cost (48.6%). When asked about the extent to which they expected that the availability of biologics for CRSwNP treatment would reduce endoscopic sinus surgery (ESS), 45.5% of members expected a reduction of approximately 10%–29%. In addition, 20.5% expected a reduction of 50% or more. However, 61.4% expected a reduction of less than 10% in primary ESS. In addition, most respondents (93.2%) agreed with the need for Korea-specific guidelines for biologic treatment.Conclusion: There are discrepancies between the current guidelines for biologic treatment of CRSwNP and the reality of the situation, highlighting the need for the development of Korea-specific guidelines.
- 30 November 2023
- Published by Korean Rhinologic Society in Journal of Rhinology
- Vol. 30 (3) , 155-160
Open AccessA Survey on Biologics for the Treatment of Chronic Rhinosinusitis With Nasal Polyps Among Members of the Korean Rhinologic Society
Background and Objectives: In 2021, biologics were approved for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in Korea. However, CRS is a heterogeneous disease, and its characteristics are thought to differ between Western and Korean populations. This study aimed to evaluate the experiences of members of the Korean Rhinologic Society during the first year of biologic usage for the treatment of nasal polyps.Methods: An anonymous survey consisting of 15 items was conducted from November to December 2021. The survey included questions about participant demographics, use of biologics for treating CRSwNP, and expectations regarding the effectiveness of biologics for treating CRSwNP.Results: In total, 44 members participated in the survey. Approximately half of the respondents were in their 40s (50.0%) and had 5–9 years of clinical experience as otorhinolaryngologists (47.7%). The majority of participants held academic positions (95.4%). About half of them worked in Gyeonggi Province. The utilization of biologics did not differ significantly based on clinical experience (p=0.192). When asked about the factors considered for prescribing biologics, the most common reason was recurrence of polyps after surgery (87.2%). The most frequent reason for discontinuing biologics was cost (48.6%). When asked about the extent to which they expected that the availability of biologics for CRSwNP treatment would reduce endoscopic sinus surgery (ESS), 45.5% of members expected a reduction of approximately 10%–29%. In addition, 20.5% expected a reduction of 50% or more. However, 61.4% expected a reduction of less than 10% in primary ESS. In addition, most respondents (93.2%) agreed with the need for Korea-specific guidelines for biologic treatment.Conclusion: There are discrepancies between the current guidelines for biologic treatment of CRSwNP and the reality of the situation, highlighting the need for the development of Korea-specific guidelines.
- Open Access
- 10 September 2023
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 66 (9) , 532-536
Treatment with biological products for chronic rhinosinusitis with nasal polyp
Background: Chronic rhinosinusitis (CRS) is further classified as CRS with nasal polyp and CRS without nasal polyp. It is also divided into type 2 and none-type 2 by immunological endotype. Nowadays, novel biological products targeting type 2 inflammation are developed and used for the treatment of CRS with nasal polyp.Current Concepts: Dupilumab, which inhibits interleukin-4 and interleukin-13, and omalizumab, which targets immunoglobulin E, were recently approved and are currently being used as the treatment regimen for patients with recurrent CRS with nasal polyp in Korea. Many studies demonstrated enough effects of both biological products on nasal symptoms, including smell, quality of life, and polyp size. The indication of biological products is refractory CRS with nasal polyp with severe symptoms even after endoscopic sinus surgery. However, the main drawback of these biological products is a high cost since they are non-reimbursement regimens as defined by Korean national health insurance.Discussion and Conclusion: Further research on the use of dupilumab and omalizumab in Korean patients will be needed because the Korean CRS endotype, which is characterized by less-type-2 CRS, is different from Western CRS endotypes. Additionally, investigations on the comparison of efficacy among various biological products are essential to prescribe the most appropriate biological products depending on the patients’ endotypes.
- 10 September 2023
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 66 (9) , 532-536
Open AccessTreatment with biological products for chronic rhinosinusitis with nasal polyp
Background: Chronic rhinosinusitis (CRS) is further classified as CRS with nasal polyp and CRS without nasal polyp. It is also divided into type 2 and none-type 2 by immunological endotype. Nowadays, novel biological products targeting type 2 inflammation are developed and used for the treatment of CRS with nasal polyp.Current Concepts: Dupilumab, which inhibits interleukin-4 and interleukin-13, and omalizumab, which targets immunoglobulin E, were recently approved and are currently being used as the treatment regimen for patients with recurrent CRS with nasal polyp in Korea. Many studies demonstrated enough effects of both biological products on nasal symptoms, including smell, quality of life, and polyp size. The indication of biological products is refractory CRS with nasal polyp with severe symptoms even after endoscopic sinus surgery. However, the main drawback of these biological products is a high cost since they are non-reimbursement regimens as defined by Korean national health insurance.Discussion and Conclusion: Further research on the use of dupilumab and omalizumab in Korean patients will be needed because the Korean CRS endotype, which is characterized by less-type-2 CRS, is different from Western CRS endotypes. Additionally, investigations on the comparison of efficacy among various biological products are essential to prescribe the most appropriate biological products depending on the patients’ endotypes.
- Open Access
- 1 January 2023
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 94-108
Effects of Neutrophil and Eosinophil Extracellular Trap Formation on Refractoriness in Chronic Rhinosinusitis With Nasal Polyps
Cha H, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):94-108. https://doi.org/10.4168/aair.2023.15.1.94
- 1 January 2023
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 94-108
Open AccessEffects of Neutrophil and Eosinophil Extracellular Trap Formation on Refractoriness in Chronic Rhinosinusitis With Nasal Polyps
Cha H, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):94-108. https://doi.org/10.4168/aair.2023.15.1.94
- Open Access
- 29 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1009424
Intranasal inoculation of IFN-λ resolves SARS-CoV-2 lung infection via the rapid reduction of viral burden and improvement of tissue damage
Introduction: The innate immune responses of upper airway could further our understanding toward antiviral strategies against SARS-CoV-2. We characterize the potential of interferon (IFN)-λ as an innate immune inducer for the rapid clearance of SARS-CoV-2 in the lung and the therapeutic efficacy of intranasal inoculation of IFN-λ to resolve acute lung infection.Methods: Syrian golden hamsters were infected with SARS-CoV-2 and the dynamics of SARS-CoV-2 infection depending on IFN-λ inoculation were tested.Results: SARS-CoV-2-infected Syrian golden hamsters exhibited a significant decrease in body weight and high viral mRNA level at 3 days post-infection (dpi). Although viral replication was reduced completely from 7 dpi, the pathologic findings remained prominent until 14 dpi in the lung of hamsters. The transcription of IFN-λ was significantly induced in response to SARS-CoV-2 infection with the increase of IFN-stimulated genes. Intranasal inoculation of IFN-λ restricted SARS-CoV-2 replication in the lungs of infected completely from 3 dpi with markedly reduction of inflammatory cytokines. The transcriptional phenotypes were altered to the direction of damage repair and tissue remodeling in the lungs of SARS-CoV-2-infected hamsters following intranasal inoculation of IFN-λ, which improved SARS-CoV-2-caused lung damage.Conclusion: Collectively, our findings suggest that IFN-λ might be a potent innate immune inducer in the lung and intranasal inoculation of IFN-λ resolves SARS-CoV-2 infection with rapid viral clearance and improvement of lung damage.
- 29 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1009424
Open AccessIntranasal inoculation of IFN-λ resolves SARS-CoV-2 lung infection via the rapid reduction of viral burden and improvement of tissue damage
Introduction: The innate immune responses of upper airway could further our understanding toward antiviral strategies against SARS-CoV-2. We characterize the potential of interferon (IFN)-λ as an innate immune inducer for the rapid clearance of SARS-CoV-2 in the lung and the therapeutic efficacy of intranasal inoculation of IFN-λ to resolve acute lung infection.Methods: Syrian golden hamsters were infected with SARS-CoV-2 and the dynamics of SARS-CoV-2 infection depending on IFN-λ inoculation were tested.Results: SARS-CoV-2-infected Syrian golden hamsters exhibited a significant decrease in body weight and high viral mRNA level at 3 days post-infection (dpi). Although viral replication was reduced completely from 7 dpi, the pathologic findings remained prominent until 14 dpi in the lung of hamsters. The transcription of IFN-λ was significantly induced in response to SARS-CoV-2 infection with the increase of IFN-stimulated genes. Intranasal inoculation of IFN-λ restricted SARS-CoV-2 replication in the lungs of infected completely from 3 dpi with markedly reduction of inflammatory cytokines. The transcriptional phenotypes were altered to the direction of damage repair and tissue remodeling in the lungs of SARS-CoV-2-infected hamsters following intranasal inoculation of IFN-λ, which improved SARS-CoV-2-caused lung damage.Conclusion: Collectively, our findings suggest that IFN-λ might be a potent innate immune inducer in the lung and intranasal inoculation of IFN-λ resolves SARS-CoV-2 infection with rapid viral clearance and improvement of lung damage.
- Open Access
- 20 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 11875
Impact of the COVID-19 and Socioeconomic Status on Access to Care for Otorhinolaryngology Patients
Since December 2019, COVID-19 has greatly influenced public healthcare systems around the globe in various aspects, including limitation of healthcare accessibility due to lack of both human and financial resources, suspension of clinics, and fear of infection causing healthcare avoidance. The aim of this study was to investigate the impact of COVID-19 on access to healthcare for otorhinolaryngology patients from different socioeconomic status (SES) groups. Otorhinolaryngology patients’ disease severity status, diagnosed at the first hospital visit, was investigated during the pre -and post-COVID-19 pandemic era in a single medical center located in Seoul, Korea. An ordinal regression model was used to assess the impact of both SES and the COVID-19 pandemic on otorhinolaryngology diseases. Within the chronic rhinosinusitis group, lower SES was associated with a higher disease severity at the first visit compared to higher SES (OR = 3.25). During the COVID-19 pandemic, while the total number of outpatients was reduced, the severity of these ENT diseases seemed to increase compared to the pre-pandemic severity in every SES group. Our study demonstrates the negative impact a worldwide pandemic can have on healthcare inequity and disease severity, and highlights the importance of re-allocating fundamental resources for those in need during periods of public health crisis.
- 20 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 11875
Open AccessImpact of the COVID-19 and Socioeconomic Status on Access to Care for Otorhinolaryngology Patients
Since December 2019, COVID-19 has greatly influenced public healthcare systems around the globe in various aspects, including limitation of healthcare accessibility due to lack of both human and financial resources, suspension of clinics, and fear of infection causing healthcare avoidance. The aim of this study was to investigate the impact of COVID-19 on access to healthcare for otorhinolaryngology patients from different socioeconomic status (SES) groups. Otorhinolaryngology patients’ disease severity status, diagnosed at the first hospital visit, was investigated during the pre -and post-COVID-19 pandemic era in a single medical center located in Seoul, Korea. An ordinal regression model was used to assess the impact of both SES and the COVID-19 pandemic on otorhinolaryngology diseases. Within the chronic rhinosinusitis group, lower SES was associated with a higher disease severity at the first visit compared to higher SES (OR = 3.25). During the COVID-19 pandemic, while the total number of outpatients was reduced, the severity of these ENT diseases seemed to increase compared to the pre-pandemic severity in every SES group. Our study demonstrates the negative impact a worldwide pandemic can have on healthcare inequity and disease severity, and highlights the importance of re-allocating fundamental resources for those in need during periods of public health crisis.
- Open Access
- 28 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 546
Alleviation of Surgery-Induced Osteitis in Sinonasal Cavity by Dexamethasone-Loaded Poly(lactic-co-glycolic acid) (PLGA) Microparticles with Strong Calcium-Binding Affinity
For the treatment of sinus surgery-induced osteitis in chronic rhinosinusitis (CRS), oral or intranasal administration of corticoids is generally used, although it has critical limitations and unavoidable side effects. To overcome these limitations, we designed dexamethasone (Dex)-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles with bone-specific binding affinity, which could release the encapsulated Dex in a sustained manner on the exposed bone after the surgical wound in the nasal cavity. In a previous report, we prepared poly(butyl methacrylate-co-methacryloyloxyethyl phosphate) (PBMP) with both calcium-binding phosphomonoester groups and PLGA-binding butyl groups to introduce strong calcium-binding property to PLGA particles. In this study, after successful encapsulation of Dex in the PBMP-coated PLGA particles, we applied the Dex-PLGA/PBMP to the treatment of post-operative osteitis in the sinonasal cavity. The Dex-PLGA/PBMP showed more than 5-times higher binding affinity to the hydroxyapatite (HA) surface compared to the non-coated PLGA particles, without altering the morphology and encapsulation efficiency. After establishing the neo-osteogenesis mouse model by mechanical injury of the nasal mucosa, the activity of intranasally administered Dex-PLGA/PBMP was examined to inhibit the formation of undesirable new woven bone during the wound healing process. In addition, significantly lower osteocalcin activity was observed in the group treated with Dex-PLGA/PBMP, indicating decreased activation of osteoblasts. Overall, these results demonstrate that the PLGA/PBMP microparticle strategy has great potential for the treatment of CRS-related osteitis by localized corticoid delivery on the exposed bones with minimal side effects.
- 28 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 546
Open AccessAlleviation of Surgery-Induced Osteitis in Sinonasal Cavity by Dexamethasone-Loaded Poly(lactic-co-glycolic acid) (PLGA) Microparticles with Strong Calcium-Binding Affinity
For the treatment of sinus surgery-induced osteitis in chronic rhinosinusitis (CRS), oral or intranasal administration of corticoids is generally used, although it has critical limitations and unavoidable side effects. To overcome these limitations, we designed dexamethasone (Dex)-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles with bone-specific binding affinity, which could release the encapsulated Dex in a sustained manner on the exposed bone after the surgical wound in the nasal cavity. In a previous report, we prepared poly(butyl methacrylate-co-methacryloyloxyethyl phosphate) (PBMP) with both calcium-binding phosphomonoester groups and PLGA-binding butyl groups to introduce strong calcium-binding property to PLGA particles. In this study, after successful encapsulation of Dex in the PBMP-coated PLGA particles, we applied the Dex-PLGA/PBMP to the treatment of post-operative osteitis in the sinonasal cavity. The Dex-PLGA/PBMP showed more than 5-times higher binding affinity to the hydroxyapatite (HA) surface compared to the non-coated PLGA particles, without altering the morphology and encapsulation efficiency. After establishing the neo-osteogenesis mouse model by mechanical injury of the nasal mucosa, the activity of intranasally administered Dex-PLGA/PBMP was examined to inhibit the formation of undesirable new woven bone during the wound healing process. In addition, significantly lower osteocalcin activity was observed in the group treated with Dex-PLGA/PBMP, indicating decreased activation of osteoblasts. Overall, these results demonstrate that the PLGA/PBMP microparticle strategy has great potential for the treatment of CRS-related osteitis by localized corticoid delivery on the exposed bones with minimal side effects.
- Open Access
- 30 November 2021
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 14 (4) , 414-423
Feasibility of Surgical Treatment for Laryngomalacia Using the Spontaneous Respiration Technique
Objectives. In this study, we review our institutional experience with pediatric laryngomalacia (LM) and report our experiences of patients undergoing supraglottoplasty using the spontaneous respiration using intravenous anesthesia and high-flow nasal oxygen (STRIVE Hi) technique.Methods. The medical records of 29 children with LM who visited Seoul National University Hospital between January 2017 and March 2019 were retrospectively reviewed. Surgical management was performed using the STRIVE Hi technique. Intraoperative findings and postoperative surgical outcomes, including complications and changes in symptoms and weight, were analyzed.Results. Of the total study population of 29 subjects, 20 (68.9%) were female. The patients were divided according to the Onley classification as follows: type I (n=13, 44.8%), II (n=10, 34.5%), and III (n=6, 20.7%). Twenty-five patients (86.2%) had comorbidities. Seventeen patients (58.6%) underwent microlaryngobronchoscopy under STRIVE Hi anesthesia. Four patients with several desaturation events required rescue oxygenation by intermittent intubation and mask bagging during the STRIVE Hi technique. However, the procedure was completed in all patients without any severe adverse effects. Overall, 15 children (51.7%) underwent supraglottoplasty, of whom 14 (93.3%) showed symptom improvement, and their postoperative weight percentile significantly increased (P=0.026). One patient required tracheostomy immediately after supraglottoplasty due to associated neurological disease.Conclusion. The STRIVE Hi technique is feasible for supraglottoplasty in LM patients, while type III LM patients with micrognathia or glossoptosis may have a higher risk of requiring rescue oxygenation during the STRIVE Hi technique.
- 30 November 2021
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 14 (4) , 414-423
Open AccessFeasibility of Surgical Treatment for Laryngomalacia Using the Spontaneous Respiration Technique
Objectives. In this study, we review our institutional experience with pediatric laryngomalacia (LM) and report our experiences of patients undergoing supraglottoplasty using the spontaneous respiration using intravenous anesthesia and high-flow nasal oxygen (STRIVE Hi) technique.Methods. The medical records of 29 children with LM who visited Seoul National University Hospital between January 2017 and March 2019 were retrospectively reviewed. Surgical management was performed using the STRIVE Hi technique. Intraoperative findings and postoperative surgical outcomes, including complications and changes in symptoms and weight, were analyzed.Results. Of the total study population of 29 subjects, 20 (68.9%) were female. The patients were divided according to the Onley classification as follows: type I (n=13, 44.8%), II (n=10, 34.5%), and III (n=6, 20.7%). Twenty-five patients (86.2%) had comorbidities. Seventeen patients (58.6%) underwent microlaryngobronchoscopy under STRIVE Hi anesthesia. Four patients with several desaturation events required rescue oxygenation by intermittent intubation and mask bagging during the STRIVE Hi technique. However, the procedure was completed in all patients without any severe adverse effects. Overall, 15 children (51.7%) underwent supraglottoplasty, of whom 14 (93.3%) showed symptom improvement, and their postoperative weight percentile significantly increased (P=0.026). One patient required tracheostomy immediately after supraglottoplasty due to associated neurological disease.Conclusion. The STRIVE Hi technique is feasible for supraglottoplasty in LM patients, while type III LM patients with micrognathia or glossoptosis may have a higher risk of requiring rescue oxygenation during the STRIVE Hi technique.